The latest analyst update for Pacific Biosciences of California cuts the rating to Underweight and trims the price target from US$2 to US$1.50, while keeping a fair value estimate of US$2.43 per share ...
Zacks Investment Research on MSN
Here's why you should add PacBio stock to your portfolio now
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...
Ratings for Pacific Biosciences (NASDAQ:PACB) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...
Hosted on MSN
Pacific Biosciences of California (PACB) dips more than broader market: What you should know
Pacific Biosciences of California (PACB) closed at $1.33 in the latest trading session, marking a -5% move from the prior day. This move lagged the S&P 500's daily loss of 1.51%. Elsewhere, the Dow ...
Pacific Biosciences of California (PACB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate ...
MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $40.4 million in its fourth quarter. On a per-share basis, the Menlo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results